And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity

And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity

The rollercoaster starts here! The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. While the idea of using LSD, MDMA, and psilocybin (the main hallucinogenic compound in magic mushrooms) to treat mental health disorders is far from a trail-blazing concept, this whole area of research had been off limits for the better part of the last 50 years. Then, something strange happened. In 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways‘ psilocybin therapy for treatment-resistant depression. A few months later, the agency awarded BTD for Usona…

Excerpt only …
READ MORE BELOW
Source : CANNANNEW REPORT
Link to original : And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity
reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.